Pfizer, BioNTech dragged to Court over COVID vaccine patent infringement once again

Published On 2023-04-06 08:00 GMT   |   Update On 2023-04-06 08:00 GMT
Advertisement

US: Arbutus Biopharma on Tuesday sued U.S. drugmaker Pfizer Inc. and its German partner BioNTech SE in a New Jersey district court, claiming their mRNA COVID-19 vaccines infringe five of Arbutus' patents.

Arbutus, along with its licensee Genevant Sciences, is seeking damages, including reasonable royalties, over the use of lipid nanoparticle (LNP) delivery technology in Pfizer/BioNTech vaccines to carry and transfer genetic material into the body.

Advertisement

The lawsuit by Arbutus and Genevant says Pfizer/BioNTech engaged in licensing discussions for the technology but they did not "result in a settlement".

Genevant is a joint venture between Arbutus and Roivant Sciences Ltd.

Arbutus Biopharma had also sued Moderna Inc in the Delaware federal court last year, claiming the latter's mRNA COVID-19 vaccine also infringes its patents.

In its lawsuit against Moderna, Arbutus had said it was not looking to block the drugmaker from producing or distributing the vaccines but was seeking monetary damages including a reasonable royalty.

"Pfizer and BioNTech are aware that Arbutus Biopharma and Genevant Sciences have filed an action for infringement with respect to certain U.S. Patents," BioNTech told Reuters, and added that the companies would not comment on their legal strategy.

Pfizer had said earlier in the day that the company "will vigorously defend against the allegations of the lawsuit."

Arbutus declined to comment beyond the press release.

Moderna had sued Pfizer and BioNTech in August 2022 for allegedly infringing three patents related to their multibillion-dollar mRNA COVID-19 vaccines.

Pfizer and BioNtech are facing another patent infringement lawsuit related to the vaccines brought by Alnylam Pharmaceuticals Inc in March 2022.

Arbutus fell 2.6% to $2.98 on Tuesday, while Pfizer was down 1.2% and U.S.-listed shares of BioNtech dropped almost 3%

Read also: Moderna fires back at Pfizer counterclaims in COVID vaccine patent lawsuit

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News